PDC*line Pharma Presents First Clinical Results From Phase I/II trial With PDC*lung01 at ESMO 2022

Preliminary results with PDC*lung01 in monotherapy and at low dose with pembrolizumab evoke acceptable safety profile, immunological activity and promising tumour response in Non-Small Cell Lung Cancer

Related Keywords

Leuven ,Region Flamande ,Belgium ,United Kingdom ,South Korea ,France ,French ,Belgian ,Kostenloser Wertpapierhandel ,Channa Debruyne ,Saffiyah Khalique Emilie Chouinard ,Eric Halioua ,Andrew Lloyd Associates ,Lg Chem Life Sciences ,French Blood Bank ,European Society For Medical Oncology ,Non Small Cell Lung ,Objective Response Rate ,Progression Free Survival ,Non Small Cell Lung Cancer ,Medical Oncology ,Low Dose ,High Dose ,Plasmacytoid Dendritic Cells ,Prof Vansteenkiste ,Data Safety Monitoring Board ,Life Sciences ,Khalique Emilie Chouinard ,Line ,Dharma ,Presents ,First ,Linical ,Results ,Rom ,Hase ,Trial ,Ith ,Ung01 ,Osmo ,022 ,